Abstract 281P
Background
Based on Globocan 2020, prostate cancer is the second most common male cancer worldwide. One of the main treatments for localized prostate cancer patients is definitive radiotherapy. Regarding limited access to intensity modulated radiation therapy and other modern techniques in developing countries, most patients in these countries are still being treated with 3D conformal RT techniques. Considering the fact that there is association between local control and prostate cancer specific mortality, we aimed to investigate the local control in unfavorable intermediate and high risk prostate cancer patients whom underwent definitive radiotherapy with 3D conformal technique.
Methods
50 patients involved in this study. They all were treated by definitive radiotherapy with 3D conformal technique since 2014 in the Radiation Department of Hamadan University of Medical Sciences. The required data was collected through the assessment of patient's' medical records. All patients were treated using a 4-field (Box) 3D technique with a total dose of 70 Gy. Additionally, in all patients, the whole pelvis was covered in the initial phase of treatment (46Gy).
Results
After the median follow up of 45 month 13 treatment failure was seen in the study population. Bio-chemical relapse occurred in 13 patients (26%). Seven patients were found to have local recurrences (14%). Distant failure, all in bone, occurred in 6 patients (12%). The 3year BCR free survival, local failure free survival and metastases free survival were 76%, 88%, and 88% respectively. The most important factor for BCR, distant failure, and overall failure was extension of disease (T stage).
Conclusions
Our results were lower compared to the results announced in the developed countries' center. This indicates that the use of modern radiotherapy techniques has been essential in prostate cancer treatment, both due to the increased treatment effectiveness and the reduction of treatment side effects. It is vital for developing countries to plan their health care policies in a way that improves patients' access to these innovative techniques. And governments should allocate a budget for updating radiotherapy devices in their country's infrastructure planning.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R. Bayani.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract